Compared to the availability of targeted agents for ER+ or HER2+ breast cancer, treatment for TNBC is limited to cytotoxic chemotherapy which is often ineffective, leading to recurrence and death [1, 2]. This evidence concerns the gene ESR1 and breast cancer.